Research Focus Areas
Custom Synthesis of Metal/Porous Nanoparticles
Nanotoxicology
Biomedical Image Contrast Agents
Precision Nanoprobes
Molecular Nanotechnology
Custom Synthesis of Metal/Porous Nanoparticles
Standardized synthesis of Gold nanoparticles (nanoclusters, 5 nm, 10 nm, 16 nm) Silver nanoparticles (nanoclusters, 10 nm, 40 nm, 95 nm) Iron oxide nanoparticles (10 nm) Gadolinium oxide (5 nm, 10 nm) Hafnium oxide (5 nm, 10 nm) Microporous silica particles (15 nm, 50 nm, 100 nm, 400 nm) Other nanoparticles currently being optimized include …
Nanotoxicology
Nanotoxicity assessment is an integral part of designing biomedical probes. In vitro toxicity of nanoparticles is assessed using murine (L929) and human cell lines (HUVEC, RAW246.7). In vivo toxicity was assessed in zebrafish models, and in vivo biodistribution/blood pool kinetics was assessed in athymic and euthymic mouse models. Representative Publications …
Biomedical Image Contrast Agents
Scaled up the synthesis of nanoparticle contrast agents. I specialize in the synthesis of long emission lifetime, fluorescent and photoluminescent nanoparticles. This is achieved by modifying Au cores with fluorophore embedded shells or Au nanoclusters with tunable photoluminescence. Fluorescent silica particles with sizes ranging from 15 nm to 400 nm are also available. Such probes …
Precision Nanoprobes
Antibody-drug conjugates are emerging as a frontrunner in precision targeted therapeutics. However, this capability is still beyond the ability of most academic laboratories. The primary reason for this is the need to identify a precise binding site on the constant region of the antibody (Fc) for the drug molecule to be conjugated, while not affecting …
Molecular Nanotechnology
This is the current focus of my research. Utilizing anisotropic and hybrid nanoparticle architectures to introduce directionality in motion, precisely orienting targeting molecules and directed exertion of force by nanosystems. Anisotropic nanoparticles can be Janus hybrids or non-spherical nanoparticles and include rods, plates, prisms, and core-shells. This will lay the basis for nanomotors and nanomachines …
Nallathamby Lab Presents Phage-Mimicking Antibacterial Nanoparticle Results at Military Health Sciences Research Symposium 2022 in Orlando, Florida (Sept 12-15, 2022)
We are losing in an antibiotic arms race with bacteria due to the emergence and global spread of new antibiotic resistance mechanisms.1,2 At current rates of antibiotics discovery and development we will eventually lose to antibiotic-resistant strains, and by 2050, antibiotics resistant strains of bacteria will kill more patients per year than all cancers combined. …
CTSI-Think Tank Seed Funds our Efforts to facilitate CAR-T Therapy to Treat Solid Tumors.
Breast Cancer is the most widespread cancer and the second leading cause of cancer-related deaths among women in the U.S.A. As a treatment option, gene-modified T cells are under active therapeutic consideration for both hematological and solid malignancies. As of 2016, there are 17 active TCR and 103 ongoing CAR-modified T cell studies registered through …
NIH Funding Opportunities
- Undergraduate Research Education Program (UP) to Enhance Diversity in the Environmental Health Sciences (R25 Clinical Trial Not Allowed) December 7, 2023Funding Opportunity RFA-ES-23-012 from the NIH Guide for Grants and Contracts. The goal of this NIEHS undergraduate research education R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce in the environmental health sciences. To this end, this funding opportunity announcement (FOA) encourages the development of […]
- Assessment of Climate at Institutions (ACt) Award (RC2 - Clinical Trial Not Allowed) December 7, 2023Funding Opportunity PAR-24-038 from the NIH Guide for Grants and Contracts. The objective of this Notice of Funding Opportunity (NOFO) is to solicit applications to conduct institutional climate assessments using validated survey instruments and to develop action plans for positive change in the recruitment, hiring, retention, and advancement of faculty, including those from groups underrepresented […]
- Findings of Research Misconduct December 7, 2023Notice NOT-OD-24-041 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): Availability of Administrative Supplements to NIGMS-Funded Awards for Building Cloud-Based Learning Modules December 7, 2023Notice NOT-GM-24-006 from the NIH Guide for Grants and Contracts
- Request for Information (RFI): NCI Cancer Research Data Commons (CRDC) Artificial Intelligence (AI) use cases to inform an assessment of data readiness December 7, 2023Notice NOT-CA-24-017 from the NIH Guide for Grants and Contracts
- Notice of Change to First Application Due Date in PAR-23-221 "Advancing Research Careers (ARC) Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)" December 6, 2023Notice NOT-GM-24-015 from the NIH Guide for Grants and Contracts
- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed) December 6, 2023Funding Opportunity RFA-DA-25-010 from the NIH Guide for Grants and Contracts. The Notice of Funding Opportunity (NOFO) aims to support research addressing the interplay of autophagy orchestrated cell death and HIV pathogenesis with a focus on the CNS cellular immune responses influenced by acute and chronic drug use.
- Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed) December 6, 2023Funding Opportunity RFA-DA-25-009 from the NIH Guide for Grants and Contracts. The Notice of Funding Opportunity (NOFO) aims to address the interplay of autophagy orchestrated cell death and HIV pathogenesis with a focus on the CNS cellular immune responses influenced by acute and chronic drug use.
- Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) December 6, 2023Funding Opportunity RFA-CA-24-021 from the NIH Guide for Grants and Contracts. The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) soliciting UG3/UH3 applications for the pediatric arm of the Cancer Adoptive Cellular Therapy (Can-ACT) Network. The overall goal of the NOFO is to advance new […]
- Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional) December 6, 2023Funding Opportunity PAR-23-318 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new […]
Recent Comments